To evaluate the cardiac safety of anti-HER2-targeted therapy for early breast cancer; to
investigate whether trastuzumab combined with pertuzumab increases cardiac toxicity …

Purpose Trastuzumab improves survival in patients with HER2+ early breast cancer.
However, cardiotoxicity remains a concern, particularly in the curative setting, and there are …

Trastuzumab is considered a cornerstone in the treatment of human epidermal growth factor
receptor-2 (HER2)-positive breast cancer. Cardiac toxicity is an important side effect of …

Purpose of Review HER2-targeted therapies have led to improved clinical outcomes in early
and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted …

Purpose HER2-targeted therapies are associated with cardiotoxicity which is usually
asymptomatic and reversible. We report the updated cardiac safety assessment of patients …

Objective Although adjuvant trastuzumab improves survival in patients with HER2-positive
early breast cancer, there is growing concern about the long-term effect of trastuzumab …

Purpose: Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side
effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to …

Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for
operable HER2-positive breast cancer. N. Engl. J. Med. 353 (16), 1673–1684 (2005) …

Purpose HER2-targeted therapies have substantially improved the outcome of patients with
breast cancer, however, they can be associated with cardiac toxicity. Guidelines recommend …

Background Few data are available about real-life cardiotoxicity associated with sc versus iv
trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about …